Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synairgen plc
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
The UK company surged on early results in the summer – but must prove its therapy’s impact in a Phase III study
Coronavirus Notebook: EMA Publishes Veklury Clinical Data, Head Of UK Vaccines Taskforce Comes Under Fire
Transparency is the order of the day as Médecins Sans Frontières calls for more disclosure on vaccine deals signed by Sanofi/GSK and other companies.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Synairgen Research Ltd